Clinical Trial Update: Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Bevacizumab and Erlotinib in patients with recurrent or metastatic ovarian epithelial cancer, fallopian tube cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED